Biotech | September 03, 2021
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
The trial will be conducted across 10 sites in India
The trial will be conducted across 10 sites in India
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
The Stasis connected care monitoring system includes - a bedside monitor that monitors 6 vital signs, a tablet that enables intuitive monitoring, and the Stasis app that allows for remote monitoring across devices
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
Coordinated and collaborative efforts will strongly contribute to the achievement of shared goals faster: Mandaviya
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
